GLP-1 receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
=== Market value === American Metal Market predicted in 2001 that the use of nickel-free Nordic gold in Euro coinage would impact the nickel market, estimating 50,000 to 70,000 tonnes of nickel would be scrapped from obsolete coinage in 2002. The market price of nickel surged throughout 2006 and the early months of 2007; as of April 5, 2007, the metal was trading at US$52,300/tonne or $1.47/oz. The price later fell dramatically; as of September 2017, the metal was trading at $11,000/tonne, or $0.31/oz. During the 2022 Russian invasion of Ukraine, worries about sanctions on Russian nickel exports triggered a short squeeze, causing the price of nickel to quadruple in just two days, reaching US$100,000 per tonne. The London Metal Exchange cancelled contracts worth $3.9 billion and suspended nickel trading for over a week. Analyst Andy Home argued that such price shocks are exacerbated by the purity requirements imposed by metal markets: only Grade I (99.8% pure) metal can be used as a commodity on the exchanges, but most of the world's supply is either in ferro-nickel alloys or lower-grade purities. In 2024, the average nickel price is estimated by the London Metal Exchange (LME) to be $15,328 per metric ton, 7.7% less than it was in 2023. At the end of 2024, the price reached its lowest levels since 2020.
Beta hairpin Extremely common. Two antiparallel beta strands connected by a tight turn of a few amino acids between them. Greek key Four beta strands, three connected by hairpins, the fourth folded over the top. Omega loop A loop in which the residues that make up the beginning and end of the loop are very close together. Helix-loop-helix Consists of alpha helices bound by a looping stretch of amino acids. This motif is seen in transcription factors. Zinc finger Two beta strands with an alpha helix end folded over to bind a zinc ion. Important in DNA binding proteins. Helix-turn-helix Two α helices joined by a short strand of amino acids and found in many proteins that regulate gene expression. Nest Extremely common. Three consecutive amino acid residues form an anion-binding concavity. Niche Extremely common. Three or four consecutive amino acid residues form a cation-binding feature.
9-Carboxymethoxymethylguanine (CMMG) is a compound which is known as the principal metabolite of the antiviral medication aciclovir (and its prodrug valaciclovir), and has been suggested as the causative agent in the neuropsychiatric side effects sometimes associated with these medications. These are mainly suffered by patients with kidney failure or otherwise decreased kidney function, and can include psychotic reactions, hallucinations, and rarely more complex disorders such as Cotard delusion. Patients suffering these symptoms following aciclovir treatment were found to have much higher levels of CMMG than normal, and since this is the first time Cotard delusion has been linked to a drug as a side effect, this discovery may be useful in the study of Cotard delusion and its treatment.
== E == E. coli - Ecotin - EIF-W2 protein domain - electrophoresis - electroporation - ELFV dehydrogenase - Ellis–van Creveld syndrome - end labeling - endonuclease - enhancer - enterobacter ribonuclease - enzyme - epitope - ethidium bromide - evolutionary clock - evolutionary footprinting - exon - exonuclease - exosome complex - expression - expression clone - expression vector - extended ELM2 domain -
ESI has a more complex ionisation mechanism, relying heavily on droplet charge excess and as such there are many more factors to consider when exploring the cause of ion suppression. It has been widely observed that for many analytes, at high concentrations, ESI exhibits a loss of detector response linearity, perhaps due to reduced charge excess caused by analyte saturation at the droplet surface, inhibiting subsequent ejection of gas phase ions from further inside the droplet. Thus competition for space and/or charge may be considered as a source of ion suppression in ESI. Both physical and chemical properties of analytes (e.g. basicity and surface activity) determine their inherent ionisation efficiency. Biological sample matrices naturally tend to contain many endogenous species with high basicity and surface activity, hence the total concentration of these species in the sample will quickly reach levels at which ion suppression should be expected. Another explanation of ion suppression in ESI considers the physical properties of the droplet itself rather than the species present. High concentrations of interfering components give rise to an increased surface tension and viscosity, giving a reduction in desolvation (solvent evaporation), which is known to have a marked effect of ionisation efficiency.
Sources: en.wikipedia.org
== Environmental risk factors == Exposures to pesticides, metals, solvents (trichloroethylene), other toxicants (carbon disulfide), and air pollution are known factors in the development of Parkinson's disease. The World Health Organization (WHO) recommends reducing exposure to environmental factors associated with PD, including pesticides, trichloroethylene (TCE), and air pollution. Pesticides, TCE and some air pollutants appear to trigger PD pathology through their effects on key mechanisms involved in mitochondrial dysfunction, oxidative stress, and neuroinflammation. The cumulative effects of many different environmental exposures over a lifetime (the exposome) interact with underlying genetic factors to influence the development and progression of neurodegenerative diseases. The brain is particularly vulnerable to compounds that are able to cross the blood-brain barrier. Body-first and brain-first models of Parkinson's disease indicate possible connections between known environmental risk factors and PD mechanisms. Toxicants such as pesticides, industrial chemicals, and air pollution are usually inhaled, ingested, or both. In the nasal cavity and gut, they engage directly with mucosal surfaces where inflammation can occur. Pathways which can carry inflammation and toxins from the olfactory system and gut to the brain are well established. Key mechanisms are increasingly understood.
Congenital hypodysfibrinogenemia is a rare inherited disorder in which low levels (i.e. <150 mg/dl) of immunologically detected plasma fibrinogen are composed at least in part of a dysfunctional fibrinogen. The disorder reflects mutations typically in both inherited fibrinogen genes, one of which produces a dysfunctional fibrinogen, while the other produces low amounts of fibrinogen. The disorder, while having reduced penetrance, is usually more severe than congenital dysfibrinogenemia, but like the latter disorder, causes pathological episodes of bleeding and/or blood clotting.
== Origins of the term == The term AI Cold War first appeared in 2018 in an article in Wired magazine by Nicholas Thompson and Ian Bremmer. The two authors trace the emergence of the AI Cold War narrative to 2017, when China published its AI Development Plan, which included a strategy aimed at becoming the global leader in AI by 2030. While the authors acknowledge the use of AI by China to strengthen its authoritarian (totalitarian) rule, they warn against the perils for the US of engaging in an AI Cold War strategy. Thompson and Bremmer rather advocate for a technological cooperation between the US and China to encourage global standards in privacy and ethical use of AI. Shortly after the publication of the article in Wired magazine, the former U.S. Treasury Secretary Hank Paulson referred to the emergence of an ‘Economic Iron Curtain’ between the US and China, reinforcing the new AI Cold War narrative.
In 1998, Tse was convicted of transporting heroin into the United States and served nine years behind bars. Tse has been compared in prominence to Joaquín "El Chapo" Guzmán and Pablo Escobar. The U.S. supply of heroin comes mainly from foreign sources which include Southeast Asia's Golden Triangle, Southwest Asia, and Latin America. Heroin comes in two forms. The first is its chemical base form which presents itself as brown and the second is a salt form that is white. The former is mainly produced in Afghanistan and some south-west countries while the latter had a history of being produced in only south-east Asia, but has since moved to also being produced in Afghanistan. There is some suspicion white Heroin is also being produced in Iran and Pakistan, but it is not confirmed. This area of Heroin production is referred to as the Golden Crescent. Heroin is not the only drug being used in these areas. The European market has shown signs of growing use in opioids on top of the long-term heroin use. Drug traffickers produce drugs in drug laboratories and drug farms. A drug lab can range in size from small workshops to the size of small towns (such as Tranquilandia). A drug farm is a place where drug crops are grown before being made into illegal narcotics. A drug farm can range in size from smallholdings to large plantations.
== Publications == The first edition was published by the WHO on 15 May 2018, and complements the WHO Model List of Essential Medicines (EML), which was published more than 40 years earlier. More than 150 countries have adapted the WHO Model List of Essential Medicines. A second edition was published in July 2019, and a third in 2020.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.